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As translational clinical researchers familiar with the
risk-benefit of hematopoietic stem cell transplantation
in autoimmune diseases, we are intrigued by the recent
report of umbilical cord mesenchymal stem cell (UC-MSC)
transplantation in treatment-refractory systemic lupus
erythematosus nephritis by Wang and colleagues. They
report the results of an open-label single-arm multicenter
phase I/II study. This stimulated us to examine whether
collective data from this group provide sufficient
evidence for the feasibility, safety, dose rationale, and
potential efficacy of UC-MSCs to conduct a randomized
controlled trial in such patients. Results, though
confounded by variable baseline prednisone and
immuno-suppressive treatment, appear to indicate near-
term response rates of approximately 50%, which are
comparable to those seen with hematopoietic stem cell
transplantation but with less morbidity and mortality.of healthy relatives or umbilical cords donated byWang and colleagues have been in the forefront of
evaluating the potential for mesenchymal stem cells
(MSCs) to treat systemic lupus erythematosus (SLE),
based on studies in murine autoimmune disease models,
demonstrating immunomodulatory properties of MSCs
[1]. We have reviewed the additional reports published
in peer-reviewed journals from this group [2-5], together
with two protocols available on ClinicalTrials.gov
(NCT00698191 and NCT01741857) (Table 1).* Correspondence: defurst@mednet.ucla.edu
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2014Protocol NCT01741857, first posted on 26 November
2012 and updated 1 November 2013, appears to be the
protocol for the study recently published in Arthritis
Research & Therapy [1]. The report largely reflects the
protocol, although dose is not described and patient
entry criteria required a dose of prednisone of more than
20 mg/day. In the report, only 10 of 40 patients were
receiving prednisone of more than 20 mg/day, and one
dose - 1 × 106 cells per kg, infused twice 7 days apart -
was evaluated. The umbilical cord mesenchymal stem
cells (UC-MSCs) for infusion were centrally prepared by
using a well-standardized, quality-controlled method,
and infusions were well tolerated. One-year mortality
(two patients with uncontrolled SLE) and morbidity (five
serious infections) compare favorably to those seen with
hematopoietic stem cell transplantation in patients with
SLE [6].
Previously reported studies by this group [2-5]
evaluated stem cells derived from either bone marrow
healthy consenting mothers in patients with treatment-
refractory SLE. Most patients had active SLE nephritis
despite receiving prednisone of more than 20 mg and
immuno-suppression with cyclophosphamide, mycophe-
nylate mofetil, or leflunomide or a combination of these.
In addition, they usually received ‘conditioning’ by cyclo-
phosphamide 0.8 to 1.8 mg/kg per day for 3 days prior
to transplant. In contrast, in the recently reported study
[1], only UC-MSCs were transplanted, without ‘condi-
tioning’, in patients with active treatment-refractory SLE
nephritis receiving a more variable background of prednis-
one, often less than 20 mg/day, and immunosuppression.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Overview of open-label phase I/II studies to evaluate mesenchymal stem cells (1 × 106 per kg) in treatment-
































2 to 4 days
0/0 Percentage of Treg
cells increased at
















0/0 Percentage of Treg
cells increased at
1 week and 3 and















versus 2× (7 days
apart)
CYC 10 mg/kg
per day, day 4,
3, and 2




























No 3/4 ND MCR 13/PCR
11, 7 relapse
aPharmacodynamic (PD) markers = increased peripheral blood regulatory T (Treg) cells, balanced T helper 1 (Th1)/Th2 cytokines; b[2] baseline (BL) proteinuria 3.1
(±1.2) g/day versus 3 months, 1.3 (±0.9) g/day (P <0.001, n = 15); [3] BL proteinuria 2.7 (±1.2) g/day versus 6 months, 0.9 (±0.8) g/day (P <0.01, n = 12); cprotocol
described at ClinicalTrials.gov consistent with this study, but not explicitly noted in report. BM, bone marrow; CR, complete remission; CYC, cyclophosphamide;
MCR, major clinical response; MSC, mesenchymal stem cell; ND, not done; NR, not reported; PCR, partial clinical response; SLEDAI, Systemic Lupus Erythematosus
Disease Activity Index; SLEN, systemic lupus erythematosus nephritis; UC, umbilical cord.
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clinical response (MCR) required that prednisone be ta-
pered to less than 10 mg/day, while maintaining improve-
ments in disease activity measured by British Isles Lupus
Assessment Group and Systemic Lupus Erythematosus
Disease Activity Index, conditioning is apparently not
needed. However, because 18 of 40 patients were receiving
prednisone of less than 20 mg/day at the start of the study,
the efficacy criterion of ‘tapered’ prednisone is difficult to
assess. Although 24 responses - 13 MCR and 11 partial
clinical response (CR) - are reported, 6 MCR and 6 partial
CR cannot be verified in the reported data, because pred-
nisone tapering appears not to meet criteria for response.
In addition, relapse occurred within a year in 6 patients,
most receiving at least 20 mg prednisone at baseline.
Nevertheless, there may be some evidence for potential ef-
ficacy or perhaps corticosteroid sparing, but dose regimen
results are not sufficiently clear, or defined by relevant
pharmacodynamic activity, to identify a specific UC-MSC
dose to use for a randomized controlled trial (RCT).
Review of previous reports may provide some add-
itional insight (Table 1). One open-label study indicates
that UC-MSCs and bone marrow mesenchymal stromal
cells, each dosed at 1 × 106 cells per kg, are equally ef-
fective, based on CR rate [4]. In the same study, patients
were randomly assigned in an unblinded manner to re-
ceive a single infusion versus two infusions of MSC,
7 days apart; again, no significant difference in CR ratewas observed. Of interest are two studies that reported
(Table 1) a significant decrease in proteinuria and an in-
crease in peripheral blood regulatory T (Foxp3) cells 3
to 6 months after infusion, potentially providing evi-
dence of a pharmacodynamic effect of MSCs [2,3]. No
correlations with improvement in clinical status were
reported, however.
Overall, Wang and colleagues have demonstrated the
feasibility of a multicenter trial, as they apparently re-
cruited a sufficient number of patients in a reasonable
period of time, and safety was acceptable. Apparently,
conditioning pre-MSC dosing is not required, although
this aspect of the treatment has not been studied in a
controlled manner. It should be pointed out that the col-
lective published results may reflect the fact that some
of the same patients were reported in more than one
study. For example, two publications [1,4] refer to the
same NCT00698191 protocol; thus, recruitment feasibil-
ity may be optimistic. The dose of stem cells, with bio-
logic activity shown in two studies, may have been
defined, although it is not absolutely clear (see above ca-
veats). There are also some indications of an appropriate
population, but again there seems to be some lack of
clarity based on the recently published study [1] where
the endpoints were not actually met.
The lack of a well-rationalized dosing regimen,
together with a lack of results from an appropriately
designed, well-controlled study, makes it extremely
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MSCs. Nevertheless, we feel that these results should
not be discarded without a proper RCT. Although there
may be some challenges in designing a well-controlled,
double-blind, placebo-controlled RCT in patients with
prednisone-dependent active SLE nephritis, this should
be attempted [7].
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